Compare Regeneron Pharmaceuticals Inc (REGN) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Tenet Healthcare Corporation — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Tenet Healthcare Corporation trades at $269.36 (market cap $20.86B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4× Tenet Healthcare Corporation's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| REGN | THC | |
|---|---|---|
Market Cap | $83.43B | $20.86B |
Sector | Health | Health |
52-Week High | $852.03 | $280.77 |
52-Week Low | $555.51 | $161.37 |
Enterprise Value | $78.14B | $31.94B |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Tenet Healthcare (THC) trades at $259.06, down 2.26% today, with a bearish technical signal but strong fundamentals. The stock exhibits robust profitability with an 82.83% gross margin and 53.31% ROE, supported by three consecutive quarterly EPS beats. Recent news includes a $2.0 billion senior notes offering for refinancing and participation in the Wells Fargo Healthcare Conference.
Outlook remains positive given analyst consensus of 81.25% buy ratings and a $281.44 price target, implying 8.6% upside. Risks include debt refinancing execution and healthcare regulatory pressures, but earnings momentum and valuation multiples below industry averages present a compelling opportunity for value investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
